Current medical research and opinion
-
The topical 5% lidocaine medicated plaster is recommended as first-line treatment for localized peripheral neuropathic pain. ⋯ Treatment of several, primarily neuropathic and mixed-pain conditions with the 5% lidocaine medicated plaster was found efficacious and safe. Further controlled studies, in particular where only small open-label studies or case reports are available, should be considered.
-
This open-label, phase 3b study evaluated the effectiveness and tolerability of tapentadol prolonged release and tapentadol immediate release (for acute pain episodes) for severe, chronic low back pain with or without a neuropathic pain component that was inadequately managed in patients taking World Health Organization (WHO) Step I or II analgesics or who were not regularly treated with analgesics. ⋯ Tapentadol prolonged release was well tolerated and effective for managing severe, chronic low back pain with or without a neuropathic pain component.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.
A 28-week, randomized, placebo-controlled study was performed to evaluate efficacy and tolerability of rosiglitazone in Japanese type 2 diabetes patients. ⋯ Although non-inferiority to pioglitazone up to 45 mg in efficacy was not shown, rosiglitazone was confirmed to have clinically meaningful efficacy over placebo and fewer fluid-related events than pioglitazone. The study is registered on ClinicalTrials.gov as protocol NCT00297063.
-
Meta Analysis
Characterizing and understanding body weight patterns in patients treated with pregabalin.
We examined patterns of weight change among patients treated with pregabalin for up to 1 year. ⋯ The majority of patients treated with pregabalin (150-600 mg/day) for 1 year maintained weight within ±7% baseline weight. One in six patients gained ≥7% weight from baseline, and generally exceeded 7%, 2-12 months after treatment onset.
-
Multicenter Study Clinical Trial
Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
To investigate the safety and efficacy of long-term administration of ambrisentan in Japanese adults with pulmonary arterial hypertension (PAH). ⋯ Our results suggest that long-term administration of ambrisentan is well tolerated and efficacious for Japanese adults with PAH.